If a stronger link is proven between XMRV and prostate cancer, HIV drugs may provide a possible treatment. Now, in laboratory research, four drugs already used to treat HIV infection can inhibit XMRV. HIV Drugs Could Work Against Prostate CancerĪ virus called XMRV has been found in biopsies from some prostate cancer patients. Silvestri will lead the Yerkes Division of Microbiology and Immunology and work to develop new therapies and vaccines for chronic diseases. Guido Silvestri, a leading scientist in studies of HIV and the related primate virus SIV, will become Emory's 11th Georgia Research Alliance Eminent Scholar this June. It does not store any personal data.Leading HIV Scientist is Newest GRA Eminent Scholar The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. The cookie is used to store the user consent for the cookies in the category "Performance". This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other. The cookies is used to store the user consent for the cookies in the category "Necessary". The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional". The cookie is used to store the user consent for the cookies in the category "Analytics". These cookies ensure basic functionalities and security features of the website, anonymously. Necessary cookies are absolutely essential for the website to function properly. Omer earned a doctorate in global disease epidemiology and control, a master’s degree in public health from Johns Hopkins University, and a bachelor’s degree in medicine and surgery from the Aga Khan University Medical College. National Vaccine Advisory Committee, the Public Health Committee of the Infectious Diseases Society of America, Presidential Advisory Council on Combating Antibiotic-Resistant Bacteria – Vaccine Innovation Working Group, and the World Health Organization’s Expert Advisory Group for Healthcare Worker Vaccination. He has served on several advisory panels including the U.S. He has received multiple awards – including the Maurice Hilleman Award by the National Foundation of Infectious Diseases for his seminal work on the impact of maternal influenza immunization on respiratory illness in infants younger than 6 months – for whom there is no vaccine. Moreover, he has written op-eds for publications such as the New York Times, Politico and the Washington Post. Omer has published approximately 250 papers in peer-reviewed journals including the New England Journal of Medicine, Journal of the American Medical Association, the Lancet, British Medical Journal, Pediatrics, American Journal of Public Health and Science. He has mentored more than 100 junior faculty, clinical and research post-doctoral fellows, Ph.D. Omer’s work has been cited in global and country-specific policy recommendations and has informed clinical practice and health legislation in several countries. Moreover, he has conducted several studies on interventions to increase immunization coverage and demand. Omer’s research portfolio includes clinical trials to estimate efficacy of maternal and/or infant influenza, pertussis, polio, measles and pneumococcal vaccines and trials to evaluate drug regimens to reduce mother-to-child transmission of HIV. Omer has conducted studies in Guatemala, Kenya, Uganda, Ethiopia, India, Pakistan, Bangladesh, South Africa and the United States. Foege chair in Global Health and professor of Global Health, Epidemiology & Pediatrics at Emory University, Schools of Public Health and Medicine. He was previously the inaugural director of the Yale Institute of Global Health and, prior to that, the William H. School of Public Health at UT Southwestern Medical Center. Omer serves as the Founding Dean of the Peter O’Donnell Jr.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |